Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.71 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.71 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | GSPT1 | P15170 | 3/20 | 0.48 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24420973 | 1.00 | CRBN (0.71) | CRBNDDB1STAT3GSPT1IKZF2 | |
| SCHEMBL20442798 | 0.95 | DDB1 (0.69) | CRBNDDB1STAT3GSPT1GPR119 | |
| SCHEMBL28909815 | 0.94 | DDB1 (0.68) | CRBNDDB1STAT3GSPT1GPR119 | |
| SCHEMBL22276597 | 0.93 | CRBN (0.66) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL20234428 | 0.89 | DDB1 (0.72) | CRBNDDB1STAT3GSPT1GPR119 | |
| SCHEMBL20325482 | 0.89 | DDB1 (0.73) | CRBNDDB1STAT3GSPT1GPR119 | |
| SCHEMBL31254134 | 0.88 | CRBN (0.65) | CRBNDDB1GSPT1IKZF2 | |
| SCHEMBL31405232 | 0.88 | CRBN (0.61) | CRBNDDB1STAT3GPR119 | |
| SCHEMBL29260150 | 0.88 | CRBN (0.61) | CRBNDDB1STAT3GPR119 | |
| SCHEMBL31240354 | 0.88 | CRBN (0.61) | CRBNDDB1STAT3GSPT1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4240743-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics, Incorporated (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |